Financials

  • Market Capitalization 132.73 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-5.07
Price to sales ratio
20.26 K

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3850
UNCY
Unicycive Therapeutics, Inc. - Common Stock
5.09 USD-2.30%-5.04%-31.59%-21.81%135.90 M USD
3864
SPRB
Spruce Biosciences, Inc. - Common Stock
48.38 USD-3.38%-6.96%-4.91%+339.82%133.16 M USD
3871
AARD
Aardvark Therapeutics, Inc. - Common Stock
5.96 USD-21.58%+1.36%+52.82%-52.74%130.03 M USD
3879
SPRO
Spero Therapeutics, Inc. - Common Stock
2.18 USD+3.81%+0.93%-25.60%-16.48%126.23 M USD

Frequently asked questions about Genelux Corporation - Common Stock

What is the Genelux Corporation - Common Stock stock price today?

The current price of Genelux Corporation - Common Stock (GNLX) is 2.96. Over the past 24 hours, the stock has changed by -2.31%. Follow the GNLX chart for real-time price dynamics.

What is the stock ticker of Genelux Corporation - Common Stock?

Genelux Corporation - Common Stock trades under the ticker GNLX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Genelux Corporation - Common Stock stock going up?

GNLX has changed by -1.66% over the last week, -1.66% over the last month, and -12.17% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Genelux Corporation - Common Stock net income for the last quarter?

Genelux Corporation - Common Stock reported net income of -8.93 M for the last quarter. The previous quarter showed -9.25 M, which means net income changed by +3.45%.

How many employees does Genelux Corporation - Common Stock have?

As of the latest available data, Genelux Corporation - Common Stock has 26 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Genelux Corporation - Common Stock stock?

You can buy Genelux Corporation - Common Stock (GNLX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Genelux Corporation - Common Stock stock?

Investing in Genelux Corporation - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the GNLX chart and related analysis on metatrader.com as part of your research.

Genelux Corporation - Common Stock

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

News